Related references
Note: Only part of the references are listed.Impact of histamine receptors H1 and H3 polymorphisms on antipsychotic-induced weight gain
Arun K. Tiwari et al.
WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY (2018)
Genetic predictors of antipsychotic response to lurasidone identified in a genome wide association study and by schizophrenia risk genes
Jiang Li et al.
SCHIZOPHRENIA RESEARCH (2018)
Long-Term Antipsychotic Use and Major Cardiovascular Events: A Retrospective Cohort Study
Alejandro G. Szmulewicz et al.
JOURNAL OF CLINICAL PSYCHIATRY (2017)
Pretreatment Cardiometabolic Status in Youth With Early-Onset Psychosis: Baseline Results From the TEA Trial
Karsten G. Jensen et al.
JOURNAL OF CLINICAL PSYCHIATRY (2017)
Lipid profile disturbances in antipsychotic-naive patients with first-episode non-affective psychosis: A systematic review and meta-analysis
Blazej Misiak et al.
SCHIZOPHRENIA RESEARCH (2017)
Lifestyle factors and the metabolic syndrome in Schizophrenia: a cross-sectional study
Adrian Heald et al.
ANNALS OF GENERAL PSYCHIATRY (2017)
Impaired Glucose Homeostasis in First-Episode Schizophrenia A Systematic Review and Meta-analysis
Toby Pillinger et al.
JAMA PSYCHIATRY (2017)
Meta-analysis reveals associations between genetic variation in the 5′ and 3′regions of Neuregulin-1 and schizophrenia
M. S. Mostaid et al.
TRANSLATIONAL PSYCHIATRY (2017)
Type I neuregulin1α is a novel local mediator to suppress hepatic gluconeogenesis in mice
Takatomo Arai et al.
SCIENTIFIC REPORTS (2017)
The Complex Inter-Relationship Between Diabetes and Schizophrenia
Jeffrey Rado
CURRENT DIABETES REVIEWS (2017)
Endogenous and Antipsychotic-Related Risks for Diabetes Mellitus in Young People With Schizophrenia: A Danish Population-Based Cohort Study
Anto P. Rajkumar et al.
AMERICAN JOURNAL OF PSYCHIATRY (2017)
Bromocriptine mitigated paliperidone metabolic and neuro-hormonal side effects and improved negative domain in a case of early onset schizophrenia
Ahmed Naguy et al.
NORDIC JOURNAL OF PSYCHIATRY (2016)
Neuregulin improves response to glucose tolerance test in control and diabetic rats
Iliana Lopez-Soldado et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2016)
Neuregulin 1 improves glucose tolerance in adult and old rats
K. Caillaud et al.
DIABETES & METABOLISM (2016)
A Naturalistic Randomized Placebo-Controlled Trial of Extended-Release Metformin to Prevent Weight Gain Associated With Olanzapine in a US Community-Dwelling Population
Jeffrey Rado et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2016)
Regulation of feeding and energy homeostasis by α-MSH
Erica J. P. Anderson et al.
JOURNAL OF MOLECULAR ENDOCRINOLOGY (2016)
The atypical antipsychotic, olanzapine, potentiates ghrelin-induced receptor signaling: An in vitro study with cells expressing cloned human growth hormone secretagogue receptor
Keita Tagami et al.
NEUROPEPTIDES (2016)
The mood stabilizer valproic acid opposes the effects of dopamine on circadian rhythms
Dominic Landgraf et al.
NEUROPHARMACOLOGY (2016)
Association Study of Serotonin 3 Receptor Subunit Gene Variants in Antipsychotic-Induced Weight Gain
Clement C. Zai et al.
NEUROPSYCHOBIOLOGY (2016)
Dopaminergic drugs in type 2 diabetes and glucose homeostasis
Felicitas Lopez Vicchi et al.
PHARMACOLOGICAL RESEARCH (2016)
Development of a Rapid Insulin Assay by Homogenous Time-Resolved Fluorescence
Zachary J. Farino et al.
PLOS ONE (2016)
Impaired glucose tolerance in first-episode drug-naive patients with schizophrenia: relationships with clinical phenotypes and cognitive deficits
D. C. Chen et al.
PSYCHOLOGICAL MEDICINE (2016)
Incidence of non-alcoholic fatty liver disease and metabolic dysfunction in first episode schizophrenia and related psychotic disorders: a 3-year prospective randomized interventional study
Maria Jose Morlan-Coarasa et al.
PSYCHOPHARMACOLOGY (2016)
Pharmacogenetic Associations of Antipsychotic Drug-Related Weight Gain: A Systematic Review and Meta-analysis
Jian-Ping Zhang et al.
SCHIZOPHRENIA BULLETIN (2016)
A review of dopamine agonist therapy in type 2 diabetes and effects on cardio-metabolic parameters
E. M. Lamos et al.
PRIMARY CARE DIABETES (2016)
Alpha-Melanocyte-Stimulating Hormone and Agouti-Related Protein: Do They Play a Role in Appetite Regulation in Childhood Obesity?
Aysel Vehapoglu et al.
JOURNAL OF CLINICAL RESEARCH IN PEDIATRIC ENDOCRINOLOGY (2016)
Pro-Opiomelanocortin (POMC) Neurones, POMC-Derived Peptides, Melanocortin Receptors and Obesity: How Understanding of this System has Changed Over the Last Decade
K. G. Mountjoy
JOURNAL OF NEUROENDOCRINOLOGY (2015)
Risperidone-induced weight gain and reduced locomotor activity in juvenile female rats: The role of histaminergic and NPY pathways
Jiamei Lian et al.
PHARMACOLOGICAL RESEARCH (2015)
Metabolic Disturbances Independent of Body Mass in Patients with Schizophrenia Taking Atypical Antipsychotics
Shi Hyun Kang et al.
PSYCHIATRY INVESTIGATION (2015)
Parameters of glucose and lipid metabolism at the fasted state in drug-naive first-episode patients with psychosis: Evidence for insulin resistance
Petros Petrikis et al.
PSYCHIATRY RESEARCH (2015)
Plasma adiponectin levels in schizophrenia and role of second-generation antipsychotics: A meta-analysis
Francesco Bartoli et al.
PSYCHONEUROENDOCRINOLOGY (2015)
Metabolic syndrome in drug-naive and drug-free patients with schizophrenia and in their siblings
Asli Enez Darcin et al.
SCHIZOPHRENIA RESEARCH (2015)
Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis
Davy Vancampfort et al.
WORLD PSYCHIATRY (2015)
Circadian Clocks as Modulators of Metabolic Comorbidity in Psychiatric Disorders
Rita Barandas et al.
CURRENT PSYCHIATRY REPORTS (2015)
Association between MC4R rs17782313 polymorphism and overeating behaviors
Z. Yilmaz et al.
INTERNATIONAL JOURNAL OF OBESITY (2015)
Association of adipokines with metabolic disorders in patients with schizophrenia: Results of comparative study with mental healthy cohort
Dmitry A. Tanyanskiy et al.
DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS (2015)
Modelling olanzapine-induced weight gain in rats
E. M. van der Zwaal et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2014)
Insulin signaling, resistance, and metabolic syndrome: insights from mouse models into disease mechanisms
Shaodong Guo
JOURNAL OF ENDOCRINOLOGY (2014)
Neuregulin-ERBB Signaling in the Nervous System and Neuropsychiatric Diseases
Lin Mei et al.
NEURON (2014)
Polymorphisms of serotonin neurotransmission and their effects on antipsychotic drug action
Hao Tang et al.
PHARMACOGENOMICS (2014)
Pharmacological Strategies to Counteract Antipsychotic-Induced Weight Gain and Metabolic Adverse Effects in Schizophrenia: A Systematic Review and Meta-analysis
Yuya Mizuno et al.
SCHIZOPHRENIA BULLETIN (2014)
Molecular pathophysiology of metabolic effects of antipsychotic medications
Jacob S. Ballon et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2014)
Circadian Clock and Stress Interactions in the Molecular Biology of Psychiatric Disorders
Dominic Landgraf et al.
CURRENT PSYCHIATRY REPORTS (2014)
Antipsychotic Induced Weight Gain: Genetics, Epigenetics, and Biomarkers Reviewed
Tahireh A. Shams et al.
CURRENT PSYCHIATRY REPORTS (2014)
Cardiometabolic Risk in Patients With First-Episode Schizophrenia Spectrum Disorders Baseline Results From the RAISE-ETP Study
Christoph U. Correll et al.
JAMA PSYCHIATRY (2014)
Metformin for Weight Loss and Metabolic Control in Overweight Outpatients With Schizophrenia and Schizoaffective Disorder
L. Fredrik Jarskog et al.
AMERICAN JOURNAL OF PSYCHIATRY (2013)
Glutamate Mediates the Function of Melanocortin Receptor 4 on Sim1 Neurons in Body Weight Regulation
Yuanzhong Xu et al.
CELL METABOLISM (2013)
The Role of Hypothalamic H1 Receptor Antagonism in Antipsychotic-Induced Weight Gain
Meng He et al.
CNS DRUGS (2013)
Effects of Antipsychotic Medications on Appetite, Weight, and Insulin Resistance
Chao Deng
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA (2013)
Metabolic risk factors in first-episode schizophrenia: baseline prevalence and course analysed from the European First-Episode Schizophrenia Trial
W. Wolfgang Fleischhacker et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2013)
Polymorphisms of the Histamine Receptor (H1HR) Gene Are Not Associated With Olanzapine-Induced Weight Gain
Beata R. Godlewska et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2013)
Weight Gain in Risperidone Therapy Investigation of Peripheral Hypothalamic Neurohormone Levels in Psychotic Patients
Tulin Yanik et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2013)
Is the Prevalence of Metabolic Syndrome and Metabolic Abnormalities Increased in Early Schizophrenia? A Comparative Meta-Analysis of First Episode, Untreated and Treated Patients
Alex J. Mitchell et al.
SCHIZOPHRENIA BULLETIN (2013)
Elevated levels of adiponectin and other cytokines in drug naive, first episode schizophrenia patients with normal weight
Xueqin Song et al.
SCHIZOPHRENIA RESEARCH (2013)
5-Hydroxytryptamine (serotonin) in the gastrointestinal tract
Michael D. Gershon
CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY (2013)
Exploring the pathogenetic association between schizophrenia and type 2 diabetes mellitus diseases based on pathway analysis
Yanli Liu et al.
BMC MEDICAL GENOMICS (2013)
Association Between Common Variants Near the Melanocortin 4 Receptor Gene and Severe Antipsychotic Drug-Induced Weight Gain
Anil K. Malhotra et al.
ARCHIVES OF GENERAL PSYCHIATRY (2012)
Life expectancy and cardiovascular mortality in persons with schizophrenia
Thomas M. Laursen et al.
CURRENT OPINION IN PSYCHIATRY (2012)
The acute effects of olanzapine on ghrelin secretion, CCK sensitivity, meal size, locomotor activity and body temperature
E. M. van der Zwaal et al.
INTERNATIONAL JOURNAL OF OBESITY (2012)
Molecular Determinants of Selectivity and Efficacy at the Dopamine D3 Receptor
Amy Hauck Newman et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Dopamine-Mediated Autocrine Inhibitory Circuit Regulating Human Insulin Secretion in Vitro
Norman Simpson et al.
MOLECULAR ENDOCRINOLOGY (2012)
Integrative role of the histaminergic system in feeding and taste perception
Tomoko Ishizuka et al.
FRONTIERS IN SYSTEMS NEUROSCIENCE (2012)
Hypoadiponectinemia: A Link between Visceral Obesity and Metabolic Syndrome
Tiziana Di Chiara et al.
JOURNAL OF NUTRITION AND METABOLISM (2012)
Olanzapine treatment and metabolic dysfunction: a dose response study in female Sprague Dawley rats
Katrina Weston-Green et al.
BEHAVIOURAL BRAIN RESEARCH (2011)
The rise and fall of the atypical antipsychotics
Tim Kendall
BRITISH JOURNAL OF PSYCHIATRY (2011)
Bromocriptine for Diabetes Mellitus Type II
Guy Valiquette
CARDIOLOGY IN REVIEW (2011)
Weight Gain and Changes in Metabolic Variables following Olanzapine Treatment in Schizophrenia and Bipolar Disorder
Leslie Citrome et al.
CLINICAL DRUG INVESTIGATION (2011)
Pharmacogenetics of Response to Antipsychotics in Patients with Schizophrenia
Maria J. Arranz et al.
CNS DRUGS (2011)
The METEOR study: frequency of metabolic disorders in patients with schizophrenia. Focus on first and second generation and level of risk of antipsychotic drugs
Bruno Falissard et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2011)
Topiramate augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study
M. R. A. Muscatello et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2011)
Dopamine Receptors in Human Adipocytes: Expression and Functions
Dana C. Borcherding et al.
PLOS ONE (2011)
The Physiology, Signaling, and Pharmacology of Dopamine Receptors
Jean-Martin Beaulieu et al.
PHARMACOLOGICAL REVIEWS (2011)
Hyperinsulinemia leads to uncoupled insulin regulation of the GLUT4 glucose transporter and the FoxO1 transcription factor
Eva Gonzalez et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Quick-Release Bromocriptine for Treatment of Type 2 Diabetes
Nasser Mikhail
CURRENT DRUG DELIVERY (2011)
Dopamine: The Forgotten Felon in Type 2 Diabetes
Sanjay Kalra et al.
RECENT PATENTS ON ENDOCRINE METABOLIC & IMMUNE DRUG DISCOVERY (2011)
Emerging role of neuregulin as a modulator of muscle metabolism
Anna Guma et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2010)
Roles of the Akt/GSK-3 and Wnt Signaling Pathways in Schizophrenia and Antipsychotic Drug Action
Zachary Freyberg et al.
AMERICAN JOURNAL OF PSYCHIATRY (2010)
Neuregulin 1-erbB4 pathway in schizophrenia: From genes to an interactome
Anamika Banerjee et al.
BRAIN RESEARCH BULLETIN (2010)
Bromocriptine: old drug, new formulation and new indication
R. I. G. Holt et al.
DIABETES OBESITY & METABOLISM (2010)
Minireview: New Roles for Peripheral Dopamine on Metabolic Control and Tumor Growth: Let's Seek the Balance
Blanca Rubi et al.
ENDOCRINOLOGY (2010)
Orally Disintegrating and Oral Standard Olanzapine Tablets Similarly Elevate the Homeostasis Model Assessment of Insulin Resistance Index and Plasma Triglyceride Levels in 12 Healthy Men: A Randomized Crossover Study
Solrun Vidarsdottir et al.
JOURNAL OF CLINICAL PSYCHIATRY (2010)
New Insights into the Endocrine and Metabolic Roles of Dopamine D2 Receptors Gained from the Drd2(-/-) Mouse
Isabel Garcia-Tornadu et al.
NEUROENDOCRINOLOGY (2010)
Increased Food Intake and Energy Expenditure Following Administration of Olanzapine to Healthy Men
Robert J. Fountaine et al.
OBESITY (2010)
Metabolic side effects of antipsychotic drug treatment - pharmacological mechanisms
Gavin P. Reynolds et al.
PHARMACOLOGY & THERAPEUTICS (2010)
Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: A double-blind, placebo-controlled trial
Preeta Kaur Narula et al.
SCHIZOPHRENIA RESEARCH (2010)
Signaling pathways in schizophrenia: emerging targets and therapeutic strategies
Caline S. Karam et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2010)
A double-blind, placebo-controlled trial of rosiglitazone for clozapine-induced glucose metabolism impairment in patients with Schizophrenia
D. C. Henderson et al.
ACTA PSYCHIATRICA SCANDINAVICA (2009)
Metabolic profile of antipsychotic-naive individuals with non-affective psychosis
Emilio Fernandez-Egea et al.
BRITISH JOURNAL OF PSYCHIATRY (2009)
Polymorphisms of Serotonin Receptor 2A and 2C Genes and COMT in Relation to Obesity and Type 2 Diabetes
Sofia I. I. Kring et al.
PLOS ONE (2009)
Association of adiponectin and metabolic syndrome among patients taking atypical antipsychotics for schizophrenia: A cohort study
Ya Mei Bai et al.
SCHIZOPHRENIA RESEARCH (2009)
AKT1 is associated with schizophrenia across multiple symptom dimensions in the Irish study of high density schizophrenia families
Dawn L. Thiselton et al.
BIOLOGICAL PSYCHIATRY (2008)
Neuropeptide Y and alpha-melanocyte-stimulating hormone: interaction in obesity and possible role in the development of hypertension
M. Baltatzi et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2008)
A review of sensitivity and tolerability of antipsychotics in patients with bipolar disorder or schizophrenia: Focus on somnolence
Keming Gao et al.
JOURNAL OF CLINICAL PSYCHIATRY (2008)
Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder:: an open randomised clinical trial
Rene S. Kahn et al.
LANCET (2008)
Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles
H. A. Nasrallah
MOLECULAR PSYCHIATRY (2008)
Association of AKT1 gene Polymorphisms with risk of schizophrenia and with response to Antipsychotics in the chinese population
Ming-Qing Xu et al.
JOURNAL OF CLINICAL PSYCHIATRY (2007)
Is dopamine a physiologically relevant mediator of feeding behavior?
Richard D. Palmiter
TRENDS IN NEUROSCIENCES (2007)
Impaired glucose tolerance in first-episode drug-naive patients with schizophrenia
L. M. Spelman et al.
DIABETIC MEDICINE (2007)
Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase
Sangwon F. Kim et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
The role of proopiomelanocortin (POMC) neurones in feeding behaviour
George W. M. Millington
NUTRITION & METABOLISM (2007)
The Akt-GSK-3 signaling cascade in the actions of doparnine
Jean-Martin Beaulieu et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2007)
Activation of dopamine D2 receptors simultaneously ameliorates various metabolic features of obese women
Petra Kok et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2006)
A role of the histaminergic system for the control of feeding by orexigenic peptides
Tomoko Ishizuka et al.
PHYSIOLOGY & BEHAVIOR (2006)
Energy expenditure and physical activity in clozapine use: implications for weight management
Jenny-Kay Sharpe et al.
AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY (2006)
Differences in resting energy expenditure and body composition between patients with schizophrenia and healthy controls
B. M. Nilsson et al.
ACTA PSYCHIATRICA SCANDINAVICA (2006)
Genetics of antipsychotic treatment emergent weight gain in schizophrenia
Daniel J. Mueller et al.
PHARMACOGENOMICS (2006)
Identifying hypothalamic pathways controlling food intake, body weight, and glucose homeostasis
JK Elmquist et al.
JOURNAL OF COMPARATIVE NEUROLOGY (2005)
Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial and comparison with national estimates from NHANES III
JP McEvoy et al.
SCHIZOPHRENIA RESEARCH (2005)
Schizophrenia and increased risks of cardiovascular disease
CH Hennekens et al.
AMERICAN HEART JOURNAL (2005)
Dopamine D2-like receptors are expressed in pancreatic beta cells and mediate inhibition of insulin secretion
B Rubí et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
An Akt/β-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior
JM Beaulieu et al.
CELL (2005)
Resting energy expenditure is lower than predicted in people taking atypical antipsychotic medication
JK Sharpe et al.
JOURNAL OF THE AMERICAN DIETETIC ASSOCIATION (2005)
Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents - A frequently sampled intravenous glucose tolerance test and minimal model analysis
DC Henderson et al.
ARCHIVES OF GENERAL PSYCHIATRY (2005)
Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis
KA Graham et al.
AMERICAN JOURNAL OF PSYCHIATRY (2005)
Convergent evidence for impaired AKT1-GSK3β signaling in schizophrenia
ES Emamian et al.
NATURE GENETICS (2004)
Defective insulin secretion and increased susceptibility to experimental diabetes are induced by reduced Akt activity in pancreatic islet β cells
E Bernal-Mizrachi et al.
JOURNAL OF CLINICAL INVESTIGATION (2004)
Expression of the two isoforms of the vesicular monoamine transporter (VMAT1 and VMAT2) in the endocrine pancreas and pancreatic endocrine tumors
M Anlauf et al.
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY (2003)
HI-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs
WK Kroeze et al.
NEUROPSYCHOPHARMACOLOGY (2003)
The role of the novel adipocyte-derived hormone adiponectin in human disease
JJ Díez et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2003)
The mode of action of thiazolidinediones
H Hauner
DIABETES-METABOLISM RESEARCH AND REVIEWS (2002)
Role of AMP-activated protein kinase in mechanism of metformin action
GC Zhou et al.
JOURNAL OF CLINICAL INVESTIGATION (2001)
Potential new treatments for type 2 diabetes
CJ Bailey
TRENDS IN PHARMACOLOGICAL SCIENCES (2000)
Share Paper
